{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T19:36:21Z","timestamp":1788550581058,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["82174063"],"award-info":[{"award-number":["82174063"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["82204703"],"award-info":[{"award-number":["82204703"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Nature Science Foundation of Anhui Province","award":["2008085MH287"],"award-info":[{"award-number":["2008085MH287"]}]},{"name":"Anhui Province Traditional Chinese Medicine Inheritance and Innovation Scientific Research Project","award":["2020cczd03"],"award-info":[{"award-number":["2020cczd03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sini-San (SNS), a classical traditional Chinese medicinal formula, has demonstrated promising potential in mitigating the progression of liver fibrosis (LF). Increasing evidence highlights that disruption of bile acids (BAs) homeostasis is critically involved in the pathogenesis and progression of LF, suggesting that targeting BAs metabolism could represent a therapeutic strategy. This study aimed to explore whether the protective effects of SNS against LF are mediated through modulation of BAs metabolism and associated regulatory pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The chemical constituents of SNS were characterized using high-performance liquid chromatography (HPLC). LF models were established in mice through intraperitoneal injection of carbon tetrachloride (CCl\n                      <jats:sub>4<\/jats:sub>\n                      ) or feeding a high-fat, high-sugar (HFHS) diet. SNS was administered orally. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and hydroxyproline (HYP) levels were measured, and liver histopathology was evaluated by hematoxylin\u2013eosin (HE), Masson and TUNEL staining. The expression of fibrosis- and apoptosis-associated markers (Collagen-1, \u03b1-SMA, Bcl-2, Bax, and Caspase-3) was assessed by RT-qPCR and Western blotting. Serum BAs profiles were analyzed using LC\u2013MS\/MS, and molecules involved in BA metabolism (Fxr, Cyp7a1, Cyp27a1, Bsep, Ntcp, Asbt and OATP) were examined. Gut microbiota composition was analyzed through 16S rRNA gene sequencing. To investigate the mechanisms by which SNS regulates BAs homeostasis, additional experiments were conducted under choline chelation, pseudo-sterile conditions, and in\n                      <jats:italic>fxr<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>\u2212\/\u2212<\/jats:italic>\n                      <\/jats:sup>\n                      mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In LF mice induced by CCl\n                      <jats:sub>4<\/jats:sub>\n                      or HFHS diet, significant alterations were observed in BAs levels and composition. The expression of BAs-synthesizing enzymes (CYP7A1, CYP27A1), BAs transporters (\n                      <jats:italic>Bsep, Ntcp, Asbt<\/jats:italic>\n                      and\n                      <jats:italic>Oatp<\/jats:italic>\n                      ), and the feedback regulatory receptor FXR was markedly dysregulated. Meanwhile, gut microbiota abundance and composition were also significantly disrupted, indicating a disturbance of BAs homeostasis. SNS treatment effectively alleviated liver injury and fibrosis, corrected BAs imbalance, regulated the expression of BAs-related genes, and restored microbial diversity. However, the antifibrotic effects of SNS were reversed by choline chelation, antibiotic treatment, and\n                      <jats:italic>fxr<\/jats:italic>\n                      knockout.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SNS may exert anti-hepatic fibrosis effects by modulating BAs metabolism and gut-liver axis pathways, ultimately restoring BAs homeostasis. These findings provide new insights into the therapeutic mechanisms of SNS and suggest its potential as a multitargeted strategy for LF treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13020-025-01252-5","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T01:02:02Z","timestamp":1762822922000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Regulatory effects of Sini-San on bile acid homeostasis in the enterohepatic circulation of mice with liver fibrosis"],"prefix":"10.1186","volume":"20","author":[{"given":"Fangsi","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijie","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rou","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengfeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"En","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingrui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoliang","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"1252_CR1","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1016\/j.cgh.2019.07.060","volume":"18","author":"AM Moon","year":"2020","unstructured":"Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol. 2020;18:2650\u201366.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1252_CR2","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3390\/cells9040875","volume":"9","author":"N Roehlen","year":"2020","unstructured":"Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells. 2020;9:875.","journal-title":"Cells"},{"key":"1252_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1080\/19490976.2019.1674124","volume":"11","author":"JA Winston","year":"2020","unstructured":"Winston JA, Theriot CM. Diversification of host bile acids by members of the gut microbiota. Gut microbes. 2020;11:158\u201371.","journal-title":"Gut microbes"},{"key":"1252_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121919","volume":"330","author":"J Zhang","year":"2023","unstructured":"Zhang J, Lyu A, Wang C. The molecular insights of bile acid homeostasis in host diseases. Life Sci. 2023;330:121919.","journal-title":"Life Sci"},{"key":"1252_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/apha.14065","volume":"240","author":"M Zhang","year":"2024","unstructured":"Zhang M, Xiao B, Chen X, Ou B, Wang S. Physical exercise plays a role in rebalancing the bile acids of enterohepatic axis in non-alcoholic fatty liver disease. Acta Physiol (Oxf). 2024;240:e14065.","journal-title":"Acta Physiol (Oxf)"},{"key":"1252_CR6","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1053\/j.gastro.2020.04.077","volume":"159","author":"DM Chopyk","year":"2020","unstructured":"Chopyk DM, Grakoui A. Contribution of the intestinal microbiome and gut barrier to hepatic disorders. Gastroenterology. 2020;159:849\u201363.","journal-title":"Gastroenterology"},{"key":"1252_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115606","volume":"168","author":"D Xiang","year":"2023","unstructured":"Xiang D, Yang J, Liu L, Yu H, Gong X, Liu D. The regulation of tissue-specific farnesoid X receptor on genes and diseases involved in bile acid homeostasis. Biomed Pharmacother. 2023;168:115606.","journal-title":"Biomed Pharmacother"},{"key":"1252_CR8","first-page":"36","volume":"54","author":"S Yu","year":"2022","unstructured":"Yu S, He J, Zhang Y. Clinical study on 42 cases of hepatic fibrosis caused by chronic hepatitis B with liver stagnation and spleen deficiency syndrome treated by Sini powder combined with Sijunzi decoction and entecavir. Jiangsu J Tradit Chin Med. 2022;54:36\u20139.","journal-title":"Jiangsu J Tradit Chin Med"},{"key":"1252_CR9","first-page":"46","volume":"9","author":"JP Liu","year":"2017","unstructured":"Liu JP, Xing WG. Treating 60 cases of fatty liver with Sini San plus the Weijing decoction. Clin J Chin Med. 2017;9:46\u20137.","journal-title":"Clin J Chin Med"},{"key":"1252_CR10","first-page":"19","volume":"39","author":"JH Wu","year":"2022","unstructured":"Wu JH, Wu XF, Zhong C, Chen XB. Effect of Ruanjian Sini Powder Combined with Transcatheter Arterial Chemoembolization on T Lymphocyte Subsets,GP-73 and GPC-3Levels in Patients with Primary Hepatocellular Carcinoma. J Guangzhou Univ Tradit Chin Med. 2022;39:19\u201324.","journal-title":"J Guangzhou Univ Tradit Chin Med"},{"key":"1252_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2022.115965","volume":"303","author":"M Jiang","year":"2023","unstructured":"Jiang M, Huang C, Wu Q, Su Y, Wang X, Xuan Z, et al. Sini san ameliorates CCl4-induced liver fibrosis in mice by inhibiting AKT-mediated hepatocyte apoptosis. J Ethnopharmacol. 2023;303:115965.","journal-title":"J Ethnopharmacol"},{"key":"1252_CR12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ab.2018.10.023","volume":"567","author":"J Wen","year":"2019","unstructured":"Wen J, Yang L, Qin F, Zhao L, Xiong Z. An integrative UHPLC-MS\/MS untargeted metabonomics combined with quantitative analysis of the therapeutic mechanism of Si-Ni-San. Anal Biochem. 2019;567:128\u201335.","journal-title":"Anal Biochem"},{"key":"1252_CR13","doi-asserted-by":"publisher","first-page":"4572","DOI":"10.1002\/ptr.7927","volume":"37","author":"Y Wang","year":"2023","unstructured":"Wang Y, Li J, Wu L, Qin X, Xie C, Gao X. Saikosaponins regulate bile acid excretion in mice liver and ileum by activating farnesoid X receptor and bile acid transporter. Phytother Res PTR. 2023;37:4572\u201386.","journal-title":"Phytother Res PTR"},{"key":"1252_CR14","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1080\/13880209.2023.2191643","volume":"61","author":"X Xu","year":"2023","unstructured":"Xu X, Hu H, Zeng H, Li B, Yin Q, Jiang Y, et al. Sinisan ameliorates colonic injury induced by water immersion restraint stress by enhancing intestinal barrier function and the gut microbiota structure. Pharm Biol. 2023;61:598\u2013609.","journal-title":"Pharm Biol"},{"key":"1252_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.118715","volume":"336","author":"A Wang","year":"2025","unstructured":"Wang A, Yang X, Lin J, Wang Y, Yang J, Zhang Y, et al. Si-Ni-San alleviates intestinal and liver damage in ulcerative colitis mice by regulating cholesterol metabolism. J Ethnopharmacol. 2025;336:118715.","journal-title":"J Ethnopharmacol"},{"key":"1252_CR16","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.3390\/nu14194180","volume":"14","author":"F Liu","year":"2022","unstructured":"Liu F, Tang X, Mao B, Zhang Q, Zhao J, Cui S, et al. Ethanol extract of licorice alleviates HFD-induced liver fat accumulation in association with modulation of gut microbiota and intestinal metabolites in obesity mice. Nutrients. 2022;14:4180.","journal-title":"Nutrients"},{"key":"1252_CR17","doi-asserted-by":"publisher","first-page":"1408459","DOI":"10.3389\/fphar.2024.1408459","volume":"15","author":"Q Wu","year":"2024","unstructured":"Wu Q, Zhu F, Yao Y, Chen L, Ding Y, Su Y, et al. Sini san regulates intestinal flora and short-chain fatty acids to ameliorate hepatocyte apoptosis and relieve CCl(4)-induced liver fibrosis in mice. Front Pharmacol. 2024;15:1408459.","journal-title":"Front Pharmacol"},{"key":"1252_CR18","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.apsb.2018.11.004","volume":"9","author":"J Zhou","year":"2019","unstructured":"Zhou J, Huang N, Guo Y, Cui S, Ge C, He Q, et al. Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis. Acta Pharm Sin B. 2019;9:526\u201336.","journal-title":"Acta Pharm Sin B"},{"key":"1252_CR19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3892\/mmr.2024.13274","volume":"30","author":"Y Su","year":"2024","unstructured":"Su Y, Zhou Q, Wu Q, Ding Y, Jiang M, Zhang X, et al. Infection-associated bile acid disturbance contributes to macrophage activation in patients with cirrhosis. Mol Med Rep. 2024;30:150.","journal-title":"Mol Med Rep"},{"key":"1252_CR20","unstructured":"2020. Pharmacopoeia of the People\u2019s Republic of China. In: Beijing: China Medical Science Press; 2020."},{"key":"1252_CR21","first-page":"65","volume":"35","author":"Y Li","year":"2019","unstructured":"Li Y, Bian T, Cao R, Niu J, Si X, Yan X. Establishment of quality standard of HPLC for Si-Ni-San powder. Chin J Clin Pharmacol. 2019;35:65\u20138.","journal-title":"Chin J Clin Pharmacol"},{"key":"1252_CR22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/s41467-023-35861-1","volume":"14","author":"M Yang","year":"2023","unstructured":"Yang M, Qi X, Li N, Kaifi JT, Chen S, Wheeler AA, et al. Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol. Nat Commun. 2023;14:228.","journal-title":"Nat Commun"},{"key":"1252_CR23","doi-asserted-by":"publisher","first-page":"9268","DOI":"10.3390\/ijms23169268","volume":"23","author":"M Ichimura-Shimizu","year":"2022","unstructured":"Ichimura-Shimizu M, Watanabe S, Kashirajima Y, Nagatomo A, Wada H, Tsuneyama K, et al. Dietary cholic acid exacerbates liver fibrosis in NASH model of Sprague-Dawley rats fed a high-fat and high-cholesterol diet. Int J Mol Sci. 2022;23:9268.","journal-title":"Int J Mol Sci"},{"key":"1252_CR24","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/gutjnl-2012-302578","volume":"62","author":"H Duboc","year":"2013","unstructured":"Duboc H, Rajca S, Rainteau D, Benarous D, Maubert MA, Quervain E, et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2013;62:531\u20139.","journal-title":"Gut"},{"key":"1252_CR25","doi-asserted-by":"publisher","first-page":"1802866","DOI":"10.1080\/19490976.2020.1802866","volume":"12","author":"A Mukherjee","year":"2020","unstructured":"Mukherjee A, Lordan C, Ross RP, Cotter PD. Gut microbes from the phylogenetically diverse genus Eubacterium and their various contributions to gut health. Gut microbes. 2020;12:1802866.","journal-title":"Gut microbes"},{"key":"1252_CR26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3350\/cmh.2022.0327","volume":"29","author":"J Yang","year":"2023","unstructured":"Yang J, Tang X, Liang Z, Chen M, Sun L. Taurocholic acid promotes hepatic stellate cell activation via S1PR2\/p38 MAPK\/YAP signaling under cholestatic conditions. Clin Mol Hepatol. 2023;29:465\u201381.","journal-title":"Clin Mol Hepatol"},{"key":"1252_CR27","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3390\/cells9020281","volume":"9","author":"S Hohenester","year":"2020","unstructured":"Hohenester S, Kanitz V, Kremer AE, Paulusma CC, Wimmer R, Kuehn H, et al. Glycochenodeoxycholate promotes liver fibrosis in mice with hepatocellular cholestasis. Cells. 2020;9:281.","journal-title":"Cells"},{"key":"1252_CR28","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.3390\/cells12101371","volume":"12","author":"MN Hasan","year":"2023","unstructured":"Hasan MN, Chen J, Wang H, Du Y, Clayton YD, Gu L, et al. Glycine-\u03b2-muricholic acid improves liver fibrosis and gut barrier function by reducing bile acid pool size and hydrophobicity in male Cyp2c70 knockout mice. Cells. 2023;12:1371.","journal-title":"Cells"},{"key":"1252_CR29","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, et al. A placebo-controlled trial of Obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631\u201343.","journal-title":"N Engl J Med"},{"key":"1252_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/foods13050699","volume":"13","author":"H Cai","year":"2024","unstructured":"Cai H, Zhang J, Liu C, Le TN, Lu Y, Feng F, et al. High-fat diet-induced decreased circulating bile acids contribute to obesity associated with gut microbiota in mice. Foods. 2024;13:699.","journal-title":"Foods"},{"key":"1252_CR31","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41579-022-00805-x","volume":"21","author":"SL Collins","year":"2023","unstructured":"Collins SL, Stine JG, Bisanz JE, Okafor CD, Patterson AD. Bile acids and the gut microbiota: metabolic interactions and impacts on disease. Nat Rev Microbiol. 2023;21:236\u201347.","journal-title":"Nat Rev Microbiol"},{"key":"1252_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.945368","volume":"12","author":"YL Zhang","year":"2022","unstructured":"Zhang YL, Li ZJ, Gou HZ, Song XJ, Zhang L. The gut microbiota-bile acid axis: a potential therapeutic target for liver fibrosis. Front Cell Infect Microbiol. 2022;12:945368.","journal-title":"Front Cell Infect Microbiol"},{"key":"1252_CR33","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1111\/liv.14453","volume":"40","author":"LA Adams","year":"2020","unstructured":"Adams LA, Wang Z, Liddle C, Melton PE, Ariff A, Chandraratna H, et al. Bile acids associate with specific gut microbiota, low-level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease. Liver Int. 2020;40:1356\u201365.","journal-title":"Liver Int"},{"key":"1252_CR34","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1111\/jcmm.14951","volume":"24","author":"X Wang","year":"2020","unstructured":"Wang X, Chen L, Wang H, Cai W, Xie Q. Modulation of bile acid profile by gut microbiota in chronic hepatitis B. J Cell Mol Med. 2020;24:2573\u201381.","journal-title":"J Cell Mol Med"},{"key":"1252_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103290","volume":"66","author":"G Xie","year":"2021","unstructured":"Xie G, Jiang R, Wang X, Liu P, Zhao A, Wu Y, et al. Conjugated secondary 12\u03b1-hydroxylated bile acids promote liver fibrogenesis. EBioMedicine. 2021;66:103290.","journal-title":"EBioMedicine"},{"key":"1252_CR36","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.3390\/nu13093143","volume":"13","author":"M Yang","year":"2021","unstructured":"Yang M, Gu Y, Li L, Liu T, Song X, Sun Y, et al. Bile acid-gut microbiota axis in inflammatory bowel disease: from bench to bedside. Nutrients. 2021;13:3143.","journal-title":"Nutrients"},{"key":"1252_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113185","volume":"151","author":"K Fu","year":"2022","unstructured":"Fu K, Ma C, Wang C, Zhou H, Gong L, Zhang Y, et al. Forsythiaside A alleviated carbon tetrachloride-induced liver fibrosis by modulating gut microbiota composition to increase short-chain fatty acids and restoring bile acids metabolism disorder. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2022;151:113185.","journal-title":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"key":"1252_CR38","doi-asserted-by":"publisher","first-page":"619","DOI":"10.4254\/wjh.v11.i8.619","volume":"11","author":"KT Vel\u00e1zquez","year":"2019","unstructured":"Vel\u00e1zquez KT, Enos RT, Bader JE, Sougiannis AT, Carson MS, Chatzistamou I, et al. Prolonged high-fat-diet feeding promotes non-alcoholic fatty liver disease and alters gut microbiota in mice. World J Hepatol. 2019;11:619\u201337.","journal-title":"World J Hepatol"},{"key":"1252_CR39","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1038\/s41396-019-0364-5","volume":"13","author":"T Ju","year":"2019","unstructured":"Ju T, Kong JY, Stothard P, Willing BP. Defining the role of Parasutterella, a previously uncharacterized member of the core gut microbiota. ISME J. 2019;13:1520\u201334.","journal-title":"ISME J"},{"key":"1252_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.137846","volume":"283","author":"M Li","year":"2024","unstructured":"Li M, Wang Q, Niu M, Yang H, Zhao S. Protective effects of insoluble dietary fiber from cereal bran against DSS-induced chronic colitis in mice: from inflammatory responses, oxidative stress, intestinal barrier, and gut microbiota. Int J Biol Macromol. 2024;283:137846.","journal-title":"Int J Biol Macromol"},{"key":"1252_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106348","volume":"182","author":"C Rodriguez-Diaz","year":"2022","unstructured":"Rodriguez-Diaz C, Taminiau B, Garc\u00eda-Garc\u00eda A, Cueto A, Robles-D\u00edaz M, Ortega-Alonso A, et al. Microbiota diversity in nonalcoholic fatty liver disease and in drug-induced liver injury. Pharmacol Res. 2022;182:106348.","journal-title":"Pharmacol Res"},{"key":"1252_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2022.111618","volume":"548","author":"JYL Chiang","year":"2022","unstructured":"Chiang JYL, Ferrell JM. Discovery of farnesoid X receptor and its role in bile acid metabolism. Mol Cell Endocrinol. 2022;548:111618.","journal-title":"Mol Cell Endocrinol"},{"key":"1252_CR43","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.cmet.2024.09.008","volume":"37","author":"L Song","year":"2025","unstructured":"Song L, Hou Y, Xu D, Dai X, Luo J, Liu Y, et al. Hepatic FXR-FGF4 is required for bile acid homeostasis via an FGFR4-LRH-1 signal node under cholestatic stress. Cell Metab. 2025;37:104-20.e9.","journal-title":"Cell Metab"},{"key":"1252_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.157108","volume":"146","author":"J Chen","year":"2025","unstructured":"Chen J, Zhang L, Chen Y, Yan Y, Lu C. Alpha-tocopheryl quinone attenuates liver fibrosis through enriching Christensenella minuta and modulating bile acids metabolism via gut-liver axis. Phytomedicine. 2025;146:157108.","journal-title":"Phytomedicine"},{"key":"1252_CR45","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41420-023-01749-8","volume":"9","author":"JL Lu","year":"2023","unstructured":"Lu JL, Yu CX, Song LJ. Programmed cell death in hepatic fibrosis: current and perspectives. Cell Death Discov. 2023;9:449.","journal-title":"Cell Death Discov"},{"key":"1252_CR46","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.2147\/DMSO.S474034","volume":"17","author":"T Liu","year":"2024","unstructured":"Liu T, Lei C, Huang Q, Song W, Li C, Sun N, et al. Hesperidin and fecal microbiota transplantation modulate the composition of the gut microbiota and reduce obesity in high fat diet mice. Diabetes Metab Syndr Obes Targets Ther. 2024;17:3643\u201356.","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"key":"1252_CR47","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3389\/fphar.2019.00268","volume":"10","author":"JB Yu","year":"2019","unstructured":"Yu JB, Zhao ZX, Peng R, Pan LB, Fu J, Ma SR, et al. Gut microbiota-based pharmacokinetics and the antidepressant mechanism of Paeoniflorin. Front Pharmacol. 2019;10:268.","journal-title":"Front Pharmacol"},{"key":"1252_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2020.153345","volume":"79","author":"Q Fan","year":"2020","unstructured":"Fan Q, Guan X, Hou Y, Liu Y, Wei W, Cai X, et al. Paeoniflorin modulates gut microbial production of indole-3-lactate and epithelial autophagy to alleviate colitis in mice. Phytomedicine. 2020;79:153345.","journal-title":"Phytomedicine"},{"key":"1252_CR49","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1210\/me.2011-1383","volume":"26","author":"N Liu","year":"2012","unstructured":"Liu N, Meng Z, Lou G, Zhou W, Wang X, Zhang Y, et al. Hepatocarcinogenesis in FXR-\/- mice mimics human HCC progression that operates through HNF1\u03b1 regulation of FXR expression. Mol Endocrinol (Baltimore, Md). 2012;26:775\u201385.","journal-title":"Mol Endocrinol (Baltimore, Md)"},{"key":"1252_CR50","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1158\/0008-5472.CAN-06-1078","volume":"67","author":"F Yang","year":"2007","unstructured":"Yang F, Huang X, Yi T, Yen Y, Moore DD, Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 2007;67:863\u20137.","journal-title":"Cancer Res"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-025-01252-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-025-01252-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-025-01252-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T01:02:05Z","timestamp":1762822925000},"score":1,"resource":{"primary":{"URL":"https:\/\/cmjournal.biomedcentral.com\/articles\/10.1186\/s13020-025-01252-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1252"],"URL":"https:\/\/doi.org\/10.1186\/s13020-025-01252-5","relation":{},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"186"}}